Skip to content
Finance Investment, Medical Health Aged Care

Investment in adult vaccination will deliver a $1.1bn net return: New report launching at Parliament House

GSK Australia < 1 mins read

WHAT

GSK Australia will launch the report, Prevention: A productive superpower – The economic value of adult vaccination in Australia, at Parliament House on Tuesday 8 October 2024.   

 

According to the new report, increasing the investment in adult immunisation will deliver high returns:

    • A $320 million net annual investment will deliver a $1.1bn return.
    • Every $1 invested in adult vaccination generates more than $3.50 in economic benefits .

 

Economic growth has slowed, inflation is rising and cost-of-living increases are placing pressure on households. Our population is ageing: demand for care and support services is escalating. These powerful economic forces have the potential to entrench structural deficits, where government spending will outweigh revenue for the foreseeable future.

Australia is at a critical decision point. Governments are making decisions on the reforms and investments that can secure our economic sustainability.

 

The launch of the report will bring together key economic leaders to assess the economic value of vaccines – including boosting productivity while reducing a range of government and social costs across health, tax, aged care, disability and carer support.

 

WHEN

Tuesday 8 October 2024

12:00pm – 1:00pm

 

LOCATION

Dame Dorothy Tangney Alcove

Parliament House, Canberra

 

WHO

The following people will be available for interviews at the launch event:

  • Dr Alan Paul - Executive Country Medical Director at GSK Australia
  • Saul Eslake - Independent economist
  • People with lived experience with preventable diseases

 

MEDIA OPPORTUNITY

There will be opportunities for interviews, photography and filming with key spokespeople at the event. Please contact the media team if you would like to organise an interview.

 

MEDIA TEAM

Juliette Bagwell

Palin Communications

0433 336 487, juliette@palin.com.au  

 

More from this category

  • Medical Health Aged Care
  • 04/10/2024
  • 06:00
Monash University

New drug could be answer to an overlooked yet devastating type of dementia

Monash University researchers are assessing a new drug that could be a game changer for the dementia that has struck US actor Bruce Willis, and countless others as young as 35: behavioural variant frontotemporal dementia (bvFTD). Unlike other types of dementia, such as Alzheimer’s Disease, there are no treatments; but a new drug — sodium selenate — was shown to be safe and well tolerated in people living with bvFTD, as outlined in the team’s 2022 study. Now,the team is announcing the next step: measuring the drug’s impact on brain functioning. While relatively rare, FTD causes progressive damage and shrinkage…

  • Medical Health Aged Care
  • 04/10/2024
  • 01:26
Dark Horse Consulting Group

Dark Horse Consulting Group Acquires BioTechLogic, Inc.

Combined organization to offer strategic advisory, operations, and technical consulting across the biopharma industryWALNUT CREEK, Calif. and CAVE CREEK, Ariz. and BOSTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHC”), the longstanding global leader in strategic and operational consulting in the field of cell and gene therapy (“CGT”), is delighted to announce the acquisition of BioTechLogic, Inc. (“BioTechLogic”), a recognized forerunner in technical operations, manufacturing, quality, and regulatory CMC consulting. This strategic acquisition marks a significant milestone in DHC’s growth, combining the complementary strengths of both teams while further consolidating DHC’s position at the vanguard of CGT.DHC—with…

  • Medical Health Aged Care
  • 03/10/2024
  • 18:26
Ferring Pharmaceuticals

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.